Skye Bioscience
SKYE
50 hedge funds and large institutions have $12.1M invested in Skye Bioscience in 2025 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 6 increasing their positions, 10 reducing their positions, and 23 closing their positions.
244% more call options, than puts
Call options by funds: $55K | Put options by funds: $16K
14% less funds holding
Funds holding: 58 → 50 (-8)
13.84% less ownership
Funds ownership: 64.16% → 50.32% (-14%)
35% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 23
40% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 10
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
85% less capital invested
Capital invested by funds: $78.1M → $12.1M (-$66M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$77.5K |
| 2 |
Two Sigma Advisers
New York
|
+$59.9K |
| 3 |
HF
HRT Financial
New York
|
+$39.9K |
| 4 |
EGM
Engineers Gate Manager
New York
|
+$33.8K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$33.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
-$3.02M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$2.44M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.79M |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
-$1.6M |
| 5 |
Mirae Asset Global ETFs Holdings
Causeway Bay,
Hong Kong
|
-$1.06M |
SKYE Hedge Fund Activity: Q4 2025 in Review
50 of the 8,225 institutional investors tracked by Wall St. Rank reported a position in Skye Bioscience (SKYE) for Q4 2025, worth a combined $12.1M — down 85% from $78.1M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of SKYE and 15 opened new positions — a net loss of 8 holders — while 10 trimmed existing stakes and 6 added.
The largest buyer was XTX Topco, opening a new position worth an estimated $77.5K. The largest seller was Ensign Peak Advisors, exiting entirely with an estimated $3.02M sold.
- 50 institutional investors held Skye Bioscience (SKYE) as of Q4 2025, down from 58 in Q3 2025.
- Funds reported $12.1M of Skye Bioscience stock for Q4 2025, down 85% quarter-over-quarter.
- 15 funds opened new Skye Bioscience positions in Q4 2025 and 23 closed out, a net change of -8 holders.
- The largest Skye Bioscience buyer in Q4 2025 was XTX Topco, an estimated $77.5K added.
- The largest Skye Bioscience seller in Q4 2025 was Ensign Peak Advisors, an estimated $3.02M sold.
Based on aggregated 13F filings for Q4 2025.